Science in telegram

🤖 A 100-billion-parameter AI model was just trained across random GPUs scattered around the globe — not in a billion-dollar datacenter. And it worked. Macrocosmos, building on the Bittensor network, has demonstrated Orion-100B: a 100B-parameter language model trained across geographically distributed Nvidia A100 GPUs. Their system, called IOTA, splits the model itself across many machines using 16 pipeline-parallel stages — unlike earlier decentralized approaches that often required each participant to host the full model. The result: more than 30% model FLOP utilization and roughly 65% of the efficiency of a comparable datacenter setup. The technical challenge was serious. Macrocosmos had to reduce massive inter-GPU traffic, handle unstable nodes, work with heterogeneous hardware, and keep the training process alive across a decentralized network. Their ResBM activation compression technique reportedly reduced traffic from around 150MB to 2.2MB per stage. The team says it ran more than 700 experiments before scaling from a 1.5B test model to 100B in about a month. Nikolas Bush’s Take:

This story matters far beyond the technical achievement. First, if this approach scales, it could change the economics of AI training. A 100B-parameter model trained on geographically distributed A100 GPUs at roughly 65% of comparable datacenter efficiency is not yet a replacement for hyperscaler infrastructure — but it is a serious signal. It suggests that large-scale AI training may not always require a single billion-dollar GPU cluster. Second, the Bittensor layer is important. This is not just a distributed computing experiment; it is an incentive system. GPU owners can be rewarded for contributing compute, which creates the foundation for a market around idle hardware. In simple terms, this could become something like “Airbnb for AI training”: monetizing unused GPU capacity the way Airbnb monetized unused rooms. Third, the uncomfortable part: decentralized AI training has often been dismissed by the mainstream AI community as impractical. Orion-100B does not prove that decentralized training will beat datacenters tomorrow. But it does prove that the idea deserves to be taken much more seriously. The next phase — permissionless participation from consumer hardware — will be the real test. If that works, the AI infrastructure map could become much more distributed than many people expected.

Original report: https://macrocosmosai.substack.com/p/orion-100b-distributed-pretraining Summary: https://www.tao.media/macrocosmos-unveils-orion-100b-a-100b-parameter-distributed-ai-training-run/ #AI #DecentralizedAI #Bittensor #LLM #DeepLearning @science

🧬 AI-Designed Universal Coronavirus Vaccine Passes First Human Trial Researchers at the University of Cambridge and their spinout DIOSynVax have just completed the first-ever human trial of a vaccine whose active ingredient was designed entirely by artificial intelligence. The results, published in the Journal of Infection, show the vaccine is safe, well-tolerated, and generates immune responses against not just one coronavirus — but an entire family of them. Unlike traditional vaccines that chase after individual variants, this vaccine uses an AI-designed "super-antigen." Machine learning algorithms analysed genetic data from every known Sarbeco coronavirus — the family that includes SARS-CoV-2, SARS, and multiple bat coronaviruses with pandemic potential — and stitched together their shared molecular features into a single immune-training molecule. The result: one shot that teaches the body to recognise the whole family, including viruses that haven't jumped to humans yet. The Phase 1 trial enrolled 39 healthy volunteers in Southampton and Cambridge. The vaccine was administered via a needle-free micro fluid jet — no syringes involved. Participants developed immune responses against SARS-CoV-2, the original SARS virus, and against bat coronaviruses flagged as future spillover risks. No significant side effects were reported. — First AI-designed vaccine antigen ever tested in humans — Single "super-antigen" targets the entire Sarbeco coronavirus family — Needle-free delivery via micro fluid jet — no injections required — Immune responses detected against SARS-CoV-2, SARS, and bat viruses with pandemic potential — Same platform adaptable for Ebola, influenza, and other rapidly mutating viruses "We've converted vaccine development from being reactive to being future-proof." — Professor Jonathan Heeney, Cambridge Why it matters: By the time a vaccine is developed against a circulating strain, the virus has already evolved. This AI-driven approach builds immunity against entire virus families before the next outbreak begins. If it works across coronaviruses, Ebola, and influenza, it could fundamentally change how humanity prepares for pandemics. 📄 Journal of Infection: https://www.journalofinfection.com/article/S0163-4453(26)00084-8/fulltext 📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260605023357.htm #UniversalVaccine #AIBiology #PandemicPreparedness #Coronavirus #FutureOfMedicine

🧬 "Undruggable" No More: New Pill Nearly Doubles Survival in Advanced Pancreatic Cancer For decades, pancreatic cancer has been one of medicine's most hopeless diagnoses. More than 90% of cases are driven by mutations in a gene called KRAS — a protein scientists long labeled "undruggable" because its surface is so unnaturally smooth that no drug could latch onto it. That era just ended. A new oral drug called daraxonrasib takes a brilliantly indirect approach: instead of trying to bind KRAS directly, it grabs onto a helper molecule called cyclophilin A inside the cell. That drug-protein complex then clamps onto active KRAS and physically shuts it down, silencing the "grow forever" signal at its source. The approach is so novel that it targets multiple mutant forms of RAS at once, making resistance much harder for the cancer to develop. In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had already been through prior treatment, the results were striking. Patients on daraxonrasib lived a median of 13.2 months compared to just 6.7 months on standard chemotherapy — nearly double. The drug reduced the overall risk of death by 60%. Results were presented by Revolution Medicines and published in the New England Journal of Medicine. Side effects are real — a prominent skin rash affected 86% of patients, along with mouth sores, diarrhea, and nausea — but patients on daraxonrasib were far less likely to abandon treatment than those on chemo, and reported better quality of life with less pain. — Median overall survival: 13.2 months (daraxonrasib) vs 6.7 months (chemotherapy) — 60% reduction in risk of death — Once-daily pill — no infusions, no hospital visits — Works against multiple RAS mutations simultaneously, limiting resistance — Lower treatment discontinuation rate and improved quality of life vs chemo "For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible. That narrative is rapidly changing." — Dr. Christopher Lieu, Professor of Medical Oncology, University of Colorado Why it matters: Pancreatic cancer kills 97% of patients with metastatic disease within five years. Chemotherapy has been our only real tool — a blunt instrument with brutal side effects. Daraxonrasib is the first therapy to go after the genetic engine of the disease itself. If approved, it would be the most significant advance in pancreatic cancer treatment in a generation, and the platform — hijacking cyclophilin A to reach "undruggable" targets — could open doors for dozens of other cancers driven by RAS mutations. 📄 NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260604044247.htm 📖 The Conversation: https://theconversation.com/breakthrough-drug-nearly-doubles-survival-with-advanced-pancreatic-cancer-an-oncologist-explains-how-daraxonrasib-overcame-an-undruggable-disease-283647 #PancreaticCancer #KRAS #CancerResearch #MedicalBreakthrough #science

🧬 Cancer Cells' Favorite Escape Trick Backfires — And Scientists Just Discovered How to Exploit It For decades, immunologists have operated under a simple assumption: cancer cells evade the immune system by shutting down a protein called MHC class I, which acts as a "wanted poster" for killer T cells. Without this signal, CD8+ killer T cells become blind to the tumor, allowing it to grow unchecked. But a groundbreaking study published in Nature Immunology has now flipped that assumption on its head. Researchers at Baylor College of Medicine and the University of Michigan discovered that when cancer cells silence MHC I to hide from killer T cells, they inadvertently expose themselves to a completely different immune attack. Instead of becoming invisible, the tumor cells become hyper-visible to CD4+ "helper" T cells — immune cells long thought to play only a supporting role. These helper T cells then trigger ferroptosis, a violent form of cell death driven by iron-catalyzed oxidative stress that essentially rusts the cancer cell from the inside out. The team, led by Dr. Pavan Reddy at the Dan L Duncan Comprehensive Cancer Center, validated this mechanism across mouse models, human tumor samples, and large clinical datasets from patients who had received checkpoint inhibitor therapies. The results held not only for cancer but also for graft-versus-host disease — a dangerous complication of bone marrow transplants — suggesting the finding rewires our fundamental understanding of T cell biology. — Cancer cells reduce MHC I to hide from CD8+ killer T cells — This loss makes them unexpectedly vulnerable to CD4+ helper T cells — CD4+ cells kill via ferroptosis — iron-driven oxidative destruction — The same mechanism operates in transplant complications — Clinical patient data confirms relevance to real-world outcomes "Our work, if further validated, will have implications for T cell-mediated immune responses beyond cancer and transplant immunology," said Reddy. "This may allow for the development of novel strategies that target MHC class I and CD4+ T cells." Why it matters: Many aggressive tumors become resistant to immunotherapy precisely because they drop MHC I expression. Until now, this was seen as a dead end. The new discovery suggests these "escaped" tumors may actually be the most vulnerable — if we can learn to weaponize CD4+ T cells against them. It opens a new front in cancer immunotherapy, especially for patients who have stopped responding to existing treatments. 📄 Original paper (Nature Immunology): https://doi.org/10.1038/s41590-026-02480-z 📖 Readable summary (ScienceDaily): https://www.sciencedaily.com/releases/2026/06/260603023911.htm #Immunology #CancerResearch #Immunotherapy #Science #Breakthrough

Может быть за раз подгружать 10 потов а потом кнопочку «далее» добавить?

🧬 Scientists Find the "Off Switch" That Exhausts CAR T Cells — and Show How to Flip It CAR T-cell therapy is one of the most powerful tools in modern oncology: take a patient's own immune cells, genetically reprogram them to hunt cancer, and put them back. It works wonders against some blood cancers. But against solid tumors — the majority of cancer cases — CAR T cells burn out too fast. Now, an international team has pinpointed exactly why. Researchers at Columbia University and University Hospital Tübingen, led by CAR T pioneer Prof. Michel Sadelain and Prof. Judith Feucht, screened roughly 400 transcription factors — proteins that act as master switches for gene activity inside cells. One protein stood out dramatically: NFIL3. It turned out to be a primary driver of T-cell exhaustion, the process that gradually strips engineered immune cells of their cancer-killing power. Using CRISPR/Cas9 gene editing, the team snipped out the gene responsible for NFIL3. The result? The edited CAR T cells stayed active significantly longer, multiplied more efficiently, and maintained a sustained anti-tumor assault. In mouse models, NFIL3-disabled cells delivered stronger tumor control and extended survival compared to standard CAR T cells. Key findings: — NFIL3 was identified as the dominant transcription factor driving CAR T-cell exhaustion out of ~400 candidates screened — CRISPR deletion of NFIL3 kept CAR T cells functional and proliferating for much longer periods — NFIL3-knockout CAR T cells showed superior tumor control across multiple animal models, including solid tumors — The approach targets the biology of exhaustion itself rather than the tumor type, potentially helping across many cancers "Switching off NFIL3 could be a decisive step toward significantly improving the long-term potency of CAR T cells," said Prof. Feucht. "We expect this to open up new possibilities in the treatment of cancer patients." Why it matters: CAR T therapy has been a revolution in blood cancers but has largely failed against solid tumors — breast, lung, pancreatic, brain — because the engineered cells simply don't last. This discovery offers a concrete, druggable target to make CAR T durable enough for the cancers that kill the most people. It's not a new therapy — it's a way to make the existing one finally work where it's needed most. 📄 Original paper (Cancer Discovery): https://doi.org/10.1158/2159-8290.CD-25-1524 📖 Readable summary: https://www.sciencedaily.com/releases/2026/06/260602021641.htm #CARTcell #CancerResearch #CRISPR #Immunotherapy #Oncology

🧬 Olive Oil's Dark Side: Yale Study Reveals Some "Healthy" Fats May Fuel Pancreatic Cancer A groundbreaking study from Yale School of Medicine has upended decades of nutritional thinking by showing that the type of fat you eat — not the total amount — could dramatically influence your risk of developing one of the deadliest cancers known to medicine. Researchers tested 12 different high-fat diets in mice genetically predisposed to pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. Each diet contained the same number of calories, differing only in the source of fat. What they found shocked even the research team: oleic acid, the primary fatty acid in olive oil and long celebrated as heart-healthy, significantly accelerated tumor growth in the pancreas. Meanwhile, omega-3-rich fats from fish oil slashed disease development by half. The mechanism behind this dramatic divergence lies in a form of programmed cell death called ferroptosis, which is triggered by lipid oxidation. Monounsaturated fats like oleic acid are chemically resistant to oxidation, effectively shielding cancer cells from self-destruction. Polyunsaturated fats like omega-3s, by contrast, oxidize easily — making cancer cell membranes fragile and pushing malignant cells toward ferroptotic death. The study also revealed a striking sex difference: oleic acid's tumor-promoting effects were pronounced in male mice but largely absent in females. — "It's really the type of fat that you're consuming, not just total fat content," says lead author Christian Felipe Ruiz, PhD. "Depending on the type of fat that you consume, it can go completely different ways. We found that some fats promote cancer, as we would expect, while other fats are really good at suppressing cancer." — "When we fed mice diets enriched with fish oil, we saw a 50% reduction in disease compared with mice fed a standard fat diet." Why it matters: Pancreatic cancer kills over 50,000 people annually in the US alone, with a brutal five-year survival rate of just 13%. Prevention strategies are desperately needed — especially for those at elevated risk, including people with chronic pancreatitis, obesity, late-onset diabetes, or a family history of the disease. This research, while not yet replicated in humans, opens the door to dietary interventions that could one day become powerful, low-cost prevention tools. It also serves as a reminder that "healthy" is contextual: what protects your heart may not protect your pancreas. 📄 Original paper (Cancer Discovery): https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0734 📖 Readable summary (ScienceDaily): https://www.sciencedaily.com/releases/2026/06/260601025349.htm 📖 Yale press release: https://medicine.yale.edu/news-article/type-of-fat-not-the-amount-fuels-pancreatic-cancer/ #PancreaticCancer #NutritionScience #YaleResearch #Omega3 #CancerPrevention

🧠 Scientists Discover the Hidden Molecular Switch That Keeps Alzheimer's Inflammation Stuck in Overdrive Researchers at Scripps Research Institute have identified a precise molecular mechanism that explains why the brain's immune system becomes trapped in a state of chronic, destructive inflammation in Alzheimer's disease. The discovery, published in Cell Chemical Biology, reveals that a single chemical modification to a protein called STING — at a specific building block known as cysteine 148 — acts as an "on switch" that cannot turn itself off. The brain has its own built-in immune defenses, and STING normally serves as an early-warning system against infections. But in Alzheimer's patients, the team found that STING undergoes a process called S-nitrosylation (SNO), where a nitric oxide-related molecule latches onto cysteine 148. This transforms STING into a hyperactive form — dubbed "SNO-STING" — that clusters into large complexes and continuously pumps out inflammatory signals. The researchers confirmed elevated levels of this rogue protein in postmortem human brain tissue, in human stem cell-derived brain immune cells, and in mouse models of the disease. What makes this cycle particularly vicious is that the very protein clumps associated with Alzheimer's — amyloid-beta and alpha-synuclein — can themselves trigger the S-nitrosylation of STING. Aging, air pollution, and even wildfire smoke further fuel the process by increasing nitric oxide in the brain. The result is a self-perpetuating "SNO-STORM": inflammation generates more NO, which modifies more STING, which drives even more inflammation, gradually destroying the synapses neurons use to communicate. — A single amino acid (cysteine 148) on the STING protein is the exact site of the damaging modification — Blocking SNO-STING formation in mice significantly reduced neuroinflammation — Crucially, synaptic connections between neurons were protected from degradation — the same connections whose loss correlates with cognitive decline — Unlike broad anti-inflammatory drugs, targeting cysteine 148 quiets only the pathological overactivation while leaving normal immune function intact — The same pathway was confirmed active in human Alzheimer's brain tissue and stem-cell models "This is a new and important therapeutic target for Alzheimer's disease," said senior author Stuart Lipton, the Step Family Foundation Endowed Chair at Scripps Research and a clinical neurologist. "It's exciting to see that blocking this switch in mice reduces inflammation and protects the very brain cell connections that are lost in Alzheimer's." Why it matters: Alzheimer's affects over 55 million people worldwide, yet nearly all clinical trials targeting amyloid plaques have failed or shown marginal benefit. This discovery shifts the focus to neuroinflammation as a driver — not just a bystander — of the disease. The fact that the target is a single, well-defined amino acid means drug developers have an unusually clean bullseye. Lipton's team is already working on small-molecule drugs designed to sit on cysteine 148 and prevent the SNO modification, potentially offering the first therapy that breaks the inflammation cycle without crippling the immune system. 📄 Original paper (Cell Chemical Biology): https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(26)00109-1 📖 Readable summary (ScienceDaily): https://www.sciencedaily.com/releases/2026/05/260530053424.htm #Alzheimers #Neuroscience #Neuroinflammation #STING #DrugDiscovery

🧬 Cambridge Scientists Reverse "Irreversible" Nerve Damage in Lab-Grown Human Brain-Spinal Cord Model Researchers at the University of Cambridge have built a miniature human brain-spinal cord system in the lab and used it to overturn a long-held assumption: that nerve damage in the central nervous system is permanent. The team, led by Dr. András Lakatos, grew pea-sized brain and spinal cord organoids from human stem cells and kept them physically separate. Axons from the brain tissue grew across the gap and connected with the spinal cord tissue, forming a functional neural circuit that could even trigger muscle contractions. Key findings: — Neurons could regrow damaged axons until roughly day 150 of development (mid-pregnancy equivalent). After that, a sharp decline in regenerative ability sets in — a biological switch hardwired into maturing human neurons. — The team identified the gene network responsible for this switch. When they blocked its key regulators, neurons regained the ability to grow axons again. — An existing drug, lynestrenol (a hormone currently approved for menstrual disorders), significantly improved axon regrowth when tested on the damaged neurons. — While lynestrenol itself is unlikely to be the clinical answer, it proves the principle: human neurons can be directly targeted to regenerate. Quote from Dr. Lakatos: "When the brain and spinal cord are damaged, the nerve fibers that carry movement signals rarely grow back. That's why paralysis is usually permanent. But our model shows this block can be reversed." This matters because most nerve regeneration research has relied on rodents, whose neurons behave differently from human ones. Human organoid models bridge that gap and may accelerate the path to treating conditions like spinal cord injury, motor neurone disease, and multiple sclerosis. Original paper (Cell Reports): https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00477-8 ScienceDaily summary: https://www.sciencedaily.com/releases/2026/05/260528082459.htm #neuroscience #organoids #regeneration #spinalcordinjury #cambridge

NASA’s Psyche spacecraft just used Mars as a cosmic slingshot On May 15, NASA’s Psyche spacecraft flew just 4,609 km above Mars, using the planet’s gravity to gain about 1,600 km/h — without spending extra fuel. The maneuver slightly changed Psyche’s orbit and put it on track for its real destination: asteroid 16 Psyche, a metal-rich world in the main asteroid belt. Arrival is planned for 2029. But the flyby also gave scientists something unexpected: a rare crescent view of Mars. From Psyche’s angle, the Red Planet appeared as a thin glowing arc, with sunlight scattering through dust high in the Martian atmosphere. That glow extended farther than expected, giving researchers a useful test case for future imaging. The flyby was also a full rehearsal. Psyche switched on its science instruments, tested its cameras, collected calibration data, and likely detected Mars’s bow shock — the region where solar wind crashes into the planet’s magnetic environment. Why does this mission matter? Asteroid Psyche may be the exposed metallic core of an early failed planet. If that’s true, NASA is about to study something similar to the deep iron core of Earth — a place we can never reach directly. A short visit to Mars. A big step toward the heart of a lost world. Source: ScienceDaily / NASA JPL https://www.sciencedaily.com/releases/2026/05/260525040421.htm

🤖 "Do 3-4x More, Don't Fire People" — Google DeepMind CEO Takes on AI Layoffs Demis Hassabis, CEO of Google DeepMind, has pushed back against the wave of tech layoffs being blamed on AI adoption. His argument comes down to one number: "If engineers are becoming 3-4 times more productive, then we just want to do 3-4 times more stuff — not cut people." 📊 The backdrop. Over the past six months, Amazon (~30,000 corporate roles), Block (40% of staff), Salesforce, Snap, Oracle, and Microsoft have all tied layoffs — at least partially — to AI. Meanwhile, Anthropic CEO Dario Amodei publicly predicts AI could wipe out half of all entry-level white-collar jobs. 🗣️ Hassabis isn't having it: "I have no idea why people are saying this with such confidence. Maybe there's an ulterior motive — to raise money or something." 🔬 Google walks the talk. Sundar Pichai recently revealed 75% of new code at Google is now written by AI (up from 25% in late 2024). Yet instead of layoffs, Hassabis sees opportunity: "I have a million ideas — from drug discovery in labs to game design. I'd happily take those freed-up engineers and deploy them on those kinds of problems." 💡 His core critique: laying people off because of AI is "a lack of imagination and a misunderstanding of what's actually going to happen."

This is not a story about Russian propaganda. It is a story about geology, chemical engineering, and decades of industrial investment. The global economy is built on physical inputs, not software abstractions. Titanium, uranium, palladium, neon, wheat, fertilizer, sapphire — these are the seven pillars that hold up modern life. Russia is the critical supplier of every single one. The West can talk about decoupling, pass sanctions, and issue moral condemnations. But when France quietly buys record volumes of Russian titanium, when Washington grants itself uranium waivers, when Brazil loads another ship of Russian potash — they are admitting what they cannot say out loud. Without Russia, the modern world does not transition to a bright green future. It falls back into the Stone Age. Not overnight. But faster than anyone is prepared for.

🌍 The Seven Pillars: What Happens to the World If Russia Disappears Tomorrow The West has spent several years trying to decouple from Russian industry. The results are not what they expected. In 2025, French imports of Russian titanium hit an all-time record. Brazil bought a quarter of its fertilizer from Russia. The US quietly carved out loopholes for Russian uranium until 2028. The world is not weaning itself off — it is doubling down. If Russia vanished from global supply chains tomorrow, modern civilization would not just stumble. It would collapse. Here is exactly what breaks, and in what order. 🔹 Aviation stops flying. Through VSMPO-AVISMA, Russia controls roughly 30% of the global aerospace titanium market. Before 2022, Boeing sourced ~35% of its titanium from Russia and Airbus over 50%. France bought a record €129.9 million of Russian titanium in 2025. Western aviation simply does not take off without this metal. 🔹 One in five American lightbulbs goes dark. Rosatom controls 36–40% of the world's uranium enrichment capacity. Roughly a quarter of the uranium fueling US nuclear reactors is Russian-sourced. Every fifth lightbulb in America — literally — burns because of Russian industrial processing. Washington passed a ban on Russian uranium in 2024, then immediately carved out exemptions lasting until 2028. Why? Because the United States simply does not have enrichment plants of comparable scale, and building them takes the better part of a decade. 🔹 Global harvests collapse. Russia is the world's #1 exporter of nitrogen fertilizers and #2 in potash. Brazil — an agricultural superpower — covers a full quarter of its fertilizer needs from Russian supply alone. Without Russian potash, Brazilian soybean yields could drop by up to 30%. India, Egypt, and much of Africa are in the same boat. There is no alternative supplier at this scale. The world's food system is literally fertilized by Russia. 🔹 Every fourth loaf of bread disappears. Russia is the undisputed #1 wheat exporter on the planet, shipping roughly 48 million tons in the 2024/25 season — roughly double what the United States exports. Egypt, the world's largest wheat importer, sources around 60% of its supply from Russia. Turkey, Iran, and nations across Africa depend on the same grain. One out of every four loaves of bread consumed globally was baked from Russian wheat. Remove it, and bread riots are not a metaphor. 🔹 The global auto industry seizes up. Russia supplies 40–43% of the world's palladium, the metal without which you cannot build a catalytic converter for any gasoline-powered vehicle. Norilsk Nickel alone is one of only two major producers on Earth. Opening a new palladium mine takes 5–10 years. The industry holds 3–6 months of inventory. After that, auto assembly lines from Stuttgart to Detroit go silent. Electric vehicles do not save you here — the world still runs on internal combustion. 🔹 Every microchip factory goes blind. Russia produces up to 30% of the world's high-purity neon, the gas that makes excimer lasers work — the same lasers that etch transistors onto every processor in every iPhone, server farm, and AI cluster. Without Russian neon, advanced chip lithography below 7 nanometers simply stops. There is no quick fix: building a neon purification plant from scratch takes 2–3 years. The semiconductor supply chain runs on a gas most people have never heard of. 🔹 Your smartphone screen goes blank. Through the Monocrystal plant, Russia holds nearly 30% of the world market for synthetic sapphire substrates — the transparent crystal covering your smartwatch face, protecting smartphone camera lenses, and shielding medical laser scanners. Monocrystal grows sapphire boules up to 350 kilograms using a modified Kyropoulos method that competitors cannot easily replicate. Substitute materials like Gorilla Glass cannot match sapphire's hardness and optical clarity. The glass on half the world's premium devices comes from a single factory in Stavropol.

🦑 Octopuses throw trash at each other. On purpose. Scientists discovered that during conflicts, octopuses gather sand, shells, and even leftover fish parts — then deliberately launch them at nearby octopuses. Some hits were so accurate that researchers described it as “social aggression.” So apparently the ocean floor already has: — toxic coworkers, — passive aggression, — and that one colleague throwing stuff at you after a Zoom call. @science

🌕 NASA has released more than 12,000 images from the Artemis II mission to the public. The archive offers a complete visual record of humanity’s return toward the Moon — including stunning photographs of the lunar surface, Earth from deep space, spacecraft systems, and the surrounding cosmos. The collection gives a rare behind-the-scenes look at modern lunar exploration and the technologies that may shape the next era of human spaceflight. You can explore the full image archive here: NASA Artemis II Image Archive